Aravive 
Welcome,         Profile    Billing    Logout  
 3 Products   11 Diseases  3 Products   1 Trial   292 News 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
batiraxcept (AVB-500) / Aravive
AXLerate-OC, NCT04729608 / 2021-000293-28: Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Terminated
3
366
Europe, Canada, US, RoW
Batiraxcept, AVB-S6-500, Paclitaxel, Taxol, Placebo
Aravive, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Platinum-resistant Ovarian Cancer
08/23
08/23
2021-000293-28: clinical trial to evaluate the safety and efficacy of a drug under investigation called AVB S6 500 in combination with Paclitaxel in women with ovarian cancer which comes back after a platinum therapy. estudio clínico para evaluar la seguridad y eficacia de un fármaco en investigación llamado AVB S6 500 en combinación con paclitaxel en mujeres con cáncer de ovario que reaparece después de una terapia con platino.

Not yet recruiting
3
400
Europe, RoW
AVB-S6-500, AVB-S6-500, Solution for injection/infusion, Concentrate for solution for injection/infusion, Bendatax (paclitaxel Bendalis)
Aravive, Inc., Aravive, Inc.
Platinum-Resistant Recurrent Ovarian Cancer Cáncer de ovario resistente al platino y recurrente, Ovarian cancer which comes back after a platinum therapy Cáncer de ovario que reaparece después de una terapia con platino, Diseases [C] - Cancer [C04]
 
 
AVB500-OC-002, NCT03639246: Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Completed
1b/2
53
US
AVB-S6-500, Paclitaxel (Pac), Taxol, Pegylated liposomal doxorubicin (PLD), Doxil, Placebo
Aravive, Inc.
Ovarian Cancer
01/21
12/22
AVB500-RCC-003, NCT04300140: Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Checkmark Preliminary data fromP1b trial in combination with batiraxcept in clear cell RCC at SITC 2021
Nov 2021 - Nov 2021: Preliminary data fromP1b trial in combination with batiraxcept in clear cell RCC at SITC 2021
Terminated
1b/2
72
US
Batiraxcept, AVB-S6-500, Cabozantinib (Cabo), Cabometyx®, Nivolumab, Opdivo®
Aravive, Inc.
Clear Cell Renal Cell Carcinoma
08/23
08/23
AVB500-PC-005, NCT04983407: Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Terminated
1b/2
34
US
batiraxcept, AVB-S6-500, Nab paclitaxel, Abraxane, Gemcitabine
Aravive, Inc.
Pancreatic Adenocarcinoma
08/23
08/23
NCT04019288: AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Terminated
1/2
12
US
Batiraxcept, Anti-AXL Fusion Protein AVB-S6-500, AVB S6 500, AVB-500, AVB-S6-500, AVBS6500, AXL Fc Fusion Protein AVB-S6-500, RUGA-S6, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736
M.D. Anderson Cancer Center, Aravive Biologics Inc, AstraZeneca
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
10/24
10/24
COAXIN, NCT04004442: Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma

Active, not recruiting
1
19
US
Avelumab, AVB-S6-500
University of Oklahoma, Aravive, Inc., EMD Serono
Urothelial Carcinoma
04/22
09/25
NCT05826015: AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Withdrawn
1
36
NA
Paclitaxel, Taxol, Batiraxcept, AVB-500
Washington University School of Medicine, National Cancer Institute (NCI), Aravive, Inc.
Recurrent High Grade Uterine Cancer
06/29
06/34
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
batiraxcept (AVB-500) / Aravive
AXLerate-OC, NCT04729608 / 2021-000293-28: Batiraxcept (AVB-S6-500)/Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Terminated
3
366
Europe, Canada, US, RoW
Batiraxcept, AVB-S6-500, Paclitaxel, Taxol, Placebo
Aravive, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT)
Platinum-resistant Ovarian Cancer
08/23
08/23
2021-000293-28: clinical trial to evaluate the safety and efficacy of a drug under investigation called AVB S6 500 in combination with Paclitaxel in women with ovarian cancer which comes back after a platinum therapy. estudio clínico para evaluar la seguridad y eficacia de un fármaco en investigación llamado AVB S6 500 en combinación con paclitaxel en mujeres con cáncer de ovario que reaparece después de una terapia con platino.

Not yet recruiting
3
400
Europe, RoW
AVB-S6-500, AVB-S6-500, Solution for injection/infusion, Concentrate for solution for injection/infusion, Bendatax (paclitaxel Bendalis)
Aravive, Inc., Aravive, Inc.
Platinum-Resistant Recurrent Ovarian Cancer Cáncer de ovario resistente al platino y recurrente, Ovarian cancer which comes back after a platinum therapy Cáncer de ovario que reaparece después de una terapia con platino, Diseases [C] - Cancer [C04]
 
 
AVB500-OC-002, NCT03639246: Efficacy and Safety Study of AVB-S6-500 in Patients With Platinum-Resistant Recurrent Ovarian Cancer

Completed
1b/2
53
US
AVB-S6-500, Paclitaxel (Pac), Taxol, Pegylated liposomal doxorubicin (PLD), Doxil, Placebo
Aravive, Inc.
Ovarian Cancer
01/21
12/22
AVB500-RCC-003, NCT04300140: Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Checkmark Preliminary data fromP1b trial in combination with batiraxcept in clear cell RCC at SITC 2021
Nov 2021 - Nov 2021: Preliminary data fromP1b trial in combination with batiraxcept in clear cell RCC at SITC 2021
Terminated
1b/2
72
US
Batiraxcept, AVB-S6-500, Cabozantinib (Cabo), Cabometyx®, Nivolumab, Opdivo®
Aravive, Inc.
Clear Cell Renal Cell Carcinoma
08/23
08/23
AVB500-PC-005, NCT04983407: Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Terminated
1b/2
34
US
batiraxcept, AVB-S6-500, Nab paclitaxel, Abraxane, Gemcitabine
Aravive, Inc.
Pancreatic Adenocarcinoma
08/23
08/23
NCT04019288: AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Terminated
1/2
12
US
Batiraxcept, Anti-AXL Fusion Protein AVB-S6-500, AVB S6 500, AVB-500, AVB-S6-500, AVBS6500, AXL Fc Fusion Protein AVB-S6-500, RUGA-S6, Durvalumab, Imfinzi, Immunoglobulin G1, Anti-(Human Protein B7-H1) (Human Monoclonal MEDI4736 Heavy Chain), Disulfide with Human Monoclonal MEDI4736 Kappa-chain, Dimer, MEDI-4736, MEDI4736
M.D. Anderson Cancer Center, Aravive Biologics Inc, AstraZeneca
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Refractory Fallopian Tube Carcinoma, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Carcinoma
10/24
10/24
COAXIN, NCT04004442: Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma

Active, not recruiting
1
19
US
Avelumab, AVB-S6-500
University of Oklahoma, Aravive, Inc., EMD Serono
Urothelial Carcinoma
04/22
09/25
NCT05826015: AVB-500 (Batiraxcept) in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer

Withdrawn
1
36
NA
Paclitaxel, Taxol, Batiraxcept, AVB-500
Washington University School of Medicine, National Cancer Institute (NCI), Aravive, Inc.
Recurrent High Grade Uterine Cancer
06/29
06/34

Download Options